Your SlideShare is downloading. ×
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Bleeding and clotting disorders in children
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Bleeding and clotting disorders in children

733

Published on

Published in: Health & Medicine, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
733
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
73
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Bleeding and coagulation disorders in children Dr.K.V.Giridhar Associate Prof. of Pediatrics GMC. Ananthapuramu, A.P., India. 4/16/2014 1
  • 2. Definition: • Spontaneous bleeding. • Excessive & Prollanged bleeding following trauma. • Petechiae, purpura, echymosis, bruises, hematoma, hemarthrosis, IC bleeds, occult GI bleeds, melena, epistaxis.
  • 3. Bleeding disorders Coagulation disorders
  • 4. Hemostasis Tissue phase Platelet phase Clotting Phase Unstable clot Phase Clot stabilization Phase Clot retraction Phase Clot resolving Phase
  • 5. THE CLOTTING MECHANISM INTRINSIC EXTRINSIC PROTHROMBIN(II) THROMBIN(III) FIBRINOGEN FIBRIN (I) V X Tissue ThromboplastinCollagen VIIXII XI IX VIII VII PT PTT Vit.K, Live r
  • 6. Etiology • VESSEL WALL ABNORMALITIES: • PLATELETS DISORDER: • COAGULATION DISORDER:
  • 7. Vessel Abnormalities • increased vascular fragility • manifest by petechial hemorrhages of skin/mucous membranes • not life threatening bleeding 1. congenital: a. Ehlers-Danlos syndrome (AD) b. hereditary hemorrhagic telangiectasia (AD) 2. acquired: a. hypersensitive vasculitis (i) drug reaction : immune complex deposit in vessel walls(Thaizide diuetics) (ii) Henoch-Schonlein purpura b. scurvy (vit C deficiency) Lab: BT, Plt count, PT, PTT will be normal
  • 8. VESSEL WALL ABNORMALITIES: EHLERS DANLOS DISEASE: • Congenital disorder of collagen synthesis • in which capillaries are poorly supported by s/c collagen • ecchymosis are commonly observed.
  • 9. VESSEL WALL ABNORMALITIES: HERIDITARY HEMORHAGIC TELANGECTSIASIS • Dominant inherited condition. • Telengectias, are small aneurysms found on finger tips, face, nasal passages, tongue and GIT. • few people develop pulmonary A/V malformation. • Pt. develops recurrent bleeding/epistaxis/ occult GIT bleeding, leads to Iron def. anemia Rx. • Iron therapy for blood loss. • Local cautery/laser therapy for single lesion • Estrogens may be tried.
  • 10. Henoch-Schonlein purpura (nonthrombocytopenic) • generalized hypersensitivity vasculitis • uncertain cause(immune mediated) clinical Sx: • Purpura(palpable) • colicky abdominal pain • polyarthralgia • acute glomerulonephritis Rx: Prednisolone for2-4 weeks
  • 11. PLATELETS DISORDER: • QUANTITATIVE PLATELETS DISORDERs • QUALITATIVE PLATELET DYSFUNCTION :
  • 12. QUANTITATIVE PLATELETS DISORDER (Thrombocytopenia) Mechanisms: 1 Failure of megakaryocytic maturation. 2 Excessive platelets consumption after their release into circulation i.e ITP, DIC etc. 3 Platelets sequestration in enlarged spleen i.e HYPERSPLEENISM. S/S: · Petechial cutaneous bleeding, intracranial bleeding and oozing from mucus membrane & skin surface. · Lab: decreased platelets count and prolong bleeding time.
  • 13. (Thrombocytopenia) Causes: Marrow Disorder Aplastic anemia Hem. malignancy Myelodysplastic disorder B12 deff. Non Marrow Disorder Immune disorders ITP, Drug induced Sec: ALL, SLE Post transfusion DIC, TTP HU syndrome, Hyperspleenism Heamangiomas Sepsis Viral infection Management: Rx Underlying cause Platelet transfusion
  • 14. IDIOPATHIC THROMBOCYTOPENIC PURPURA(ITP) • An autoimmune antibody IgG is formed against unknown antigen of platelets membrane/surface. • Antipletelet antibody binds to complement, but platelets are not destroyed by direct lysis. • Destruction takes place in spleen, where spleenic macrophages destroyes antibody coated platelets.
  • 15. IDIOPATHIC THROMBOCYTOPENIC PURPURA. (Clinical Features) In Children(acute): Often precipitated by viral infection and usually self limited  Asymptomatic not febrile.  Present with mucosal/skin bleeding, mennorrhagia, purpura, petechiae . Adults(chronic):  Commonly affects female.  Ratio 2:1 (male/female ratio)
  • 16. IDIOPATHIC THROMBOCYTOPENIC PURPURA. Δ LAB: platelets below 10,000 /ml. Bone marrow will appear normal. Rx PREDNISONONE: 1-2 mg/kg/day. Immunoglobulin: 1g/kg/day 2-3 days. DANAZOLE: 600mg/day response rate is 50% IMMUNOSUPPERESSIVE DRUGS: i-e vincristine, vinblastine, azathioprine, cyclosprin, cyclophosphomide. SPLEENECTOMY: Prognosis: The prognosis will be good, if disease is initially controlled with prednisolone, spleenectomy is definite Rx.
  • 17. EVANS SYNDROME: • ITP + Autoimmune hemolytic anemia. • These pts shows spherocytosis, reticulocytosis + anemia.
  • 18. QUALITATIVE PLATELET DISORDER CONGENITAL: Glanzmann‟s thrombosthenia Bernard souliar syndrome Von Willibrand‟s disease ACQUIRED Myeloproliferative disorder. Uremia Drugs i-e NSAIDS Aspirin Autoantibody Fibrin degradation products
  • 19. QUALITATIVE PLATELET DISORDER BERNARD SOULIER SYNDROME: Autosomal recessive intrinsic platelets disorder. Due to lack of glycoprotein (Gp1b), receptor for vonWillibrand‟s factor. Clinical Features: Presents with mucosal bleeding and post operative oozes. LAB: Thrombocytopenia may be present, and Plt.s are abnormally large in size. BT is prolonged Von Willibrand’s factor Normal Rx: Platelet transfusion
  • 20. QUALITATIVE PLATELET DISORDER GLANZMANN’s THROMBASTHENIA: Autosomal recessive disorder. Lack of receptors (glycoprotein Ib & IIIa) for fibrinogen on platelets. Platelets fails to aggregate in respons to ADP, collagen, thrombin. Clinical Features: Mucosal bleeding LAB: Platelets no‟s and morphology are normal B.T is prolonged Rx: Platelet transfusion
  • 21. QUALITATIVE PLATELET DISORDER VON-WILLIBRAND’S DISEASE: • Autosomal dominant(gene for vWF is located on chromosome 12.) • vWF is synthesized by endothelial cells and megakaryocytes • It acts as carrier protein for factor VIII by non-covalent bond. A defect therefore leads to decreased plasma factor VIII level. • It also forms bridges b/w platelets and sub endothelium. • There fore defect of vWF leads to prolonged bleeding.
  • 22. VON-WILLIBRAND’S DISEASE: Clinical Features: • Mucosal bleeding (mild-massive) LAB: • Reduced level of vWF which often accomplished by sec: reduction in factor VIII and prolonged bleeding time (B.T) Rx: • MILD HAEMORRHAGES: Desmopressin 0.3 μg/kg, after which vWF levels usually raise 3 in 30-90 minutes • MASSIVE HAEMORRHAGES: Factor VIII
  • 23. COAGULATION DISORDER: Coagulation factor disorder can either due to single factor def., i.e. a “congenitaldeficiency”, eg factor VIII resulting in HAEMOPHILIA-A or due to multiple factor def., which is an „‟acquired” eg Sec: to liver disease or warfarin therapy.
  • 24. • HEAMOPHILIA – A (CLASSIC TRUE HAEMOPHILIA) • HAEMOPHILLIA – B (CHRISTMAS DISEASE). • X-linked recessive Inheritance. COAGULATION DISORDER: CONGENITAL BLEEDING DISORDER:
  • 25. HEAMOPHILIA – A (CLASSIC TRUE HAEMOPHILIA) • X-linked disorder • Due to deff. of factor VIII C/F: • Bleeding occurs as bruising at the age of 6 months. • Trauma results in excessively bleeding. • Recurrent bleeding /hemorrhage in knee, elbow, ankle, and hip. (Hemarthrosis) • Mucus membrane /internal bleeding of mouth, lips, gums, brain and kidney also occur • Muscle haematoma esp. calf and Psoas muscle Rx • Factor VIII infusion
  • 26. Hemophilia A
  • 27. HAEMOPHILLIA – B (CHRISTMAS DISEASE) • Due to deff: of factor IX S/S: • Same in type A Rx • Factor IX infusion LONG TERM COMPLICATION COMPLICATION due to repeated hemorrhage: • Arthropathy of large joints eg knee, elbow • Muscle atrophy due to haematoma • Mononeuropathy due to pressure of haematoma. COMPLICATION due to therapy • Antifactor VIII antibody develops • Virus transmission Hepatitis A-B-C-D + HIV
  • 28. COAGULATION DISORDER ACQUIRED BLEEDING DISORDER • DIC • LIVER DISEASE • RENAL DISEASE
  • 29. DISSAMINATED INTRAVASCULAR COAGULATION • DIC is condition characterized by thrombosis within circulation. • DIC can be induced by different mechanisms. • Due to Endothelial cell damage by endotoxins in G –ve septicemia results in tissue factor release which in turn leads to coagulation cascade activation through extrinsic pathway. • The presence thromboplastin from damaged tissue, placenta & fat embolus (following brain injury & Fractures) may activate coagulation • This results in excessive consumption of platelets and coagulation factors, with secondary activation of fibrinolysis leading to bleeding tendency.
  • 30. DIC: CAUSES Infectious: • E Coli • Nessieria meningitis • Strep pneumonia • Malaria Cancer • Lung,Pancreas, • Prostate CLINICAL FEATURES: Bleeding & thrombosis, bleeding is more than thrombosis. Subacute DIC: Occurs primarily in cancerous pts results in superficial + deep venous thrombosis. Other Manifestation: High incidence of cardio respiratory failure
  • 31. DIC LAB: • Thrombocytopenia • Prolong PT • APTT may be normal/increased • Low fibrinogen • Increased level FDP/D-dimmer
  • 32. Treatment of DIC Rx. Underlying cause. General Measures: • Correction of dehydration • Renal failure • Acidosis and • Shock Replacement: • Platelets transfusion if platelets counts below 10,000/l • cryoprecipitate to maintain plasma fibrinogen level above 150 mg/dl • FFP • Heparin, if there is DVT, Pulmonarythrombosis.
  • 33. Approach to a child with bleeding disorder Bleeding Not sick sick Superficial bleeds Deep Bleeds CBC, BT Factor assay, Gene analysis Bone marrow Blood culture CBC, Bonemarrow LFT RFT FDP
  • 34. THANKYOU

×